Trial Profile
PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Letrozole; Paclitaxel; Tamoxifen
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PAMELA; SOLTI-PAMELA
- 17 May 2023 Results (TBCRC023 and PAMELA studies) hypothesizing that a multiparameter classifier can identify patients with HER2 "addicted" tumors who may benefit from a chemotherapy-sparing strategy published in the Clinical Cancer Research
- 31 May 2020 Results hypothyzing that a multiparameter classifier predicts response to lapatinib plus trastuzumab using baseline specimens from 2 trials (TBCRC023 [NCT00999804] and PAMELA [NCT01973660]) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Results of a combined analysis of CALGB40601 (Alliance) and PAMELA clinical trials, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.